erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the .
"we were quite surprised to find there were no significant differences," says study author
. 'cut short' by james taylor is published on june 1 by white owl books, price ?20.